Home › Juvenile Myelomonocytic Leukemia › Georgia › Atlanta
Juvenile Myelomonocytic Leukemia clinical trials in Atlanta, GA
3 studies for Juvenile Myelomonocytic Leukemia are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RecruitingPhase 1/2
- Children's Hospital of Atlanta, Atlanta
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
RecruitingPhase 1
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Juvenile Myelomonocytic Leukemia trials in other cities
- Minneapolis, MN4 studies
- Philadelphia, PA4 studies
- Boston, MA3 studies
- New York City, NY3 studies
- Chicago, IL3 studies
- Ann Arbor, MI3 studies
- Memphis, TN3 studies
- San Francisco, CA3 studies
- Washington, DC3 studies
- Cincinnati, OH3 studies
- Indianapolis, IN3 studies
- Seattle, WA3 studies
Other studies in Atlanta
- Cancer (all types)49 studies
- Non-Small Cell Lung Cancer47 studies
- Multiple Myeloma42 studies
- Breast Cancer41 studies
- Prostate Cancer33 studies
- Acute Myeloid Leukemia31 studies
- Ovarian Cancer29 studies
- Colorectal Cancer29 studies
- Lung Cancer29 studies
- Metastatic Cancer28 studies
- Major Depressive Disorder25 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.